High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration
{{output}}
In recent years, biologics-based modalities have increased significantly across various therapeutic areas. Monoclonal antibodies (mAbs) and emerging bioconjugates such as antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugate (AOCs) now span on... ...
